Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 21:5:178.
doi: 10.3389/fcvm.2018.00178. eCollection 2018.

C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction

Affiliations

C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction

Jessie van Wezenbeek et al. Front Cardiovasc Med. .

Abstract

Background: Impaired cardiorespiratory fitness (CRF) is a hallmark of heart failure (HF). Serum levels of C-reactive protein (CRP), a systemic inflammatory marker, and of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker of myocardial strain, independently predict adverse outcomes in HF patients. Whether CRP and/or NT-proBNP also predict the degree of CRF impairment in HF patients across a wide range of ejection fraction is not yet established. Methods: Using retrospective analysis, 200 patients with symptomatic HF who completed one or more treadmill cardiopulmonary exercise tests (CPX) using a symptom-limited ramp protocol and had paired measurements of serum high-sensitivity CRP and NT-proBNP on the same day were evaluated. Univariate and multivariate correlations were evaluated with linear regression after logarithmic transformation of CRP (log10) and NT-proBNP (logN). Results: Mean age of patients was 57 ± 10 years and 55% were male. Median CRP levels were 3.7 [1.5-9.0] mg/L, and NT-proBNP levels were 377 [106-1,464] pg/ml, respectively. Mean peak oxygen consumption (peak VO2) was 16 ± 4 mlO2•kg-1•min-1. CRP levels significantly correlated with peakVO2 in all patients (R = -0.350, p < 0.001) and also separately in the subgroup of patients with reduced left ventricular ejection fraction (LVEF) (HFrEF, N = 109) (R = -0.282, p < 0.001) and in those with preserved EF (HFpEF, N = 57) (R = -0.459, p < 0.001). NT-proBNP levels also significantly correlated with peak VO2 in all patients (R = -0.330, p < 0.001) and separately in patients with HFrEF (R = -0.342, p < 0.001) and HFpEF (R = -0.275, p = 0.032). CRP and NT-proBNP did not correlate with each other (R = 0.05, p = 0.426), but independently predicted peak VO2 (R = 0.421, p < 0.001 and p < 0.001, respectively). Conclusions: Biomarkers of inflammation and myocardial strain independently predict peak VO2 in HF patients. Anti-inflammatory therapies and therapies alleviating myocardial strain may independently improve CRF in HF patients across a large spectrum of LVEF.

Keywords: biomarker; cardiopulmonary exercise testing; cardiorespiratory fitness; heart failure; myocardial strain; systemic inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of LVEF, CRP, and NT-proBNP levels in the population. Histogram showing the distribution of (A) LVEF, (B) CRP levels, and (C) NT-proBNP levels in the population. LVEF, Left Ventricular Ejection Fraction.
Figure 2
Figure 2
CRP as predictor of CRF in HFrEF and HFpEF. Correlations are shown in (A) between CRP and Peak VO2 in patients with HFpEF (R = −0.459, P < 0.001) and with HFrEF (R = −0.282, P < 0.001) and in (B) between CRP and TET in patients with HFpEF (R = −0.345, P < 0.001) and with HFrEF (R = −0.336, P < 0.001). VO2, Oxygen uptake; HFpEF, Heart Failure with preserved Ejection Fraction; HFrEF, Heart Failure with reduced Ejection Fraction; TET, Treadmill Exercise Time.
Figure 3
Figure 3
NT-proBNP as predictor of CRF in HFrEF and HFpEF. Correlations are shown in (A) between NT-proBNP and Peak VO2 in patients with HFpEF (R = −0.275, P = 0.032) and with HFrEF (R = −0.354, P < 0.001) and in (B) between NT-proBNP and TET in patients with HFpEF (R = −0.459, P < 0.001) and with HFrEF (R = −0.437, P < 0.001). VO2, oxygen uptake; HFpEF, Heart Failure with preserved Ejection Fraction; HFrEF, Heart Failure with reduced Ejection Fraction; TET, Treadmill Exercise Time.
Figure 4
Figure 4
Discriminative value of CRP and NT-proBNP for reduced CRF. ROC curves depicting the discriminative value of CRP in (A) and of NT-proBNP in (B) for reduced CRF defined as Peak VO2 <10 mlO2•kg−1•min−1(AUC = 0.660, P = 0.014 for CRP and AUC = 0.749, P < 0.001 for NT-proBNP). ROC curves depicting the discriminative value of CRP in (C) and NT-proBNP in (D) for reduced CRF defined as Peak VO2 <14 mlO2•kg−1•min−1 (AUC = 0.658, P < 0.001 for CRP and AUC = 0.608, P = 0.003 for NT-proBNP). ROC, Receiver operating characteristic; CRF, Cardiorespiratory Fitness; VO2, oxygen uptake; AUC. Area Under the Curve.

References

    1. Kondamudi N, Haykowsky M, Forman DE, Berry JD, Pandey A. Exercise training for prevention and treatment of heart failure. Prog Cardiovasc Dis. (2017) 60:115–20. 10.1016/j.pcad.2017.07.001 - DOI - PubMed
    1. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, et al. . Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res. (2015) 117:207–19. 10.1161/CIRCRESAHA.117.305205 - DOI - PMC - PubMed
    1. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. . Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American heart association. Circulation (2010) 122:191–225. 10.1161/CIR.0b013e3181e52e69 - DOI - PubMed
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation (2002) 105:1135–43. 10.1161/hc0902.104353 - DOI - PubMed
    1. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, et al. . Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. (2016) 67:544–51. 10.1097/FJC.0000000000000378 - DOI - PMC - PubMed